IMPDH1 — inosine monophosphate dehydrogenase 1

The IMPDH1 gene provides instructions for making an enzyme called inosine monophosphate dehydrogenase 1. This enzyme acts like a tiny factory inside your cells, producing a crucial molecule called GTP. GTP is essential for many cellular processes, but it is especially important in the retina, the light-sensitive tissue at the back of the eye. The cells in the retina, called photoreceptors, need massive amounts of GTP to send visual signals to the brain. IMPDH1 works overtime in the retina to ensure these cells have enough energy and signaling molecules to function properly, especially when adjusting to different light levels. When there is a mutation (a harmful change) in the IMPDH1 gene, the enzyme may not work correctly, or it might clump together abnormally inside the photoreceptor cells. This disruption can damage the cells over time, leading to vision loss. Mutations in IMPDH1 are a known cause of a condition called retinitis pigmentosa (specifically RP10), which typically starts with night blindness and gradually leads to a loss of peripheral (side) vision, creating a "tunnel vision" effect. In some cases, it can cause a more severe, early-onset condition called Leber congenital amaurosis, which affects vision from birth or early infancy. For patients and families, an IMPDH1 mutation is usually inherited in an "autosomal dominant" pattern. This means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. If a person has an IMPDH1 mutation, each of their children has a 50% chance of inheriting it. While there is currently no cure for IMPDH1-related vision loss, knowing the specific genetic cause can help doctors predict how the disease might progress, guide the use of supportive treatments or low-vision aids, and determine if the patient might be eligible for future clinical trials or targeted therapies.

Gene description: Encodes an enzyme essential for de novo guanine nucleotide biosynthesis, critical for rapidly dividing cells like photoreceptors.

Patient and family guide: The IMPDH1 gene provides instructions for making an enzyme called inosine monophosphate dehydrogenase 1. This enzyme acts like a tiny factory inside your cells, producing a crucial molecule called GTP. GTP is essential for many cellular processes, but it is especially important in the retina, the light-sensitive tissue at the back of the eye. The cells in the retina, called photoreceptors, need massive amounts of GTP to send visual signals to the brain. IMPDH1 works overtime in the retina to ensure these cells have enough energy and signaling molecules to function properly, especially when adjusting to different light levels. When there is a mutation (a harmful change) in the IMPDH1 gene, the enzyme may not work correctly, or it might clump together abnormally inside the photoreceptor cells. This disruption can damage the cells over time, leading to vision loss. Mutations in IMPDH1 are a known cause of a condition called retinitis pigmentosa (specifically RP10), which typically starts with night blindness and gradually leads to a loss of peripheral (side) vision, creating a "tunnel vision" effect. In some cases, it can cause a more severe, early-onset condition called Leber congenital amaurosis, which affects vision from birth or early infancy. For patients and families, an IMPDH1 mutation is usually inherited in an "autosomal dominant" pattern. This means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. If a person has an IMPDH1 mutation, each of their children has a 50% chance of inheriting it. While there is currently no cure for IMPDH1-related vision loss, knowing the specific genetic cause can help doctors predict how the disease might progress, guide the use of supportive treatments or low-vision aids, and determine if the patient might be eligible for future clinical trials or targeted therapies.

Gene function: IMPDH1 encodes inosine monophosphate dehydrogenase 1, a rate-limiting enzyme in the de novo synthesis of guanine nucleotides. These nucleotides are crucial for DNA and RNA synthesis, energy metabolism, and signal transduction. In the retina, photoreceptor cells have high metabolic activity and require a constant supply of guanine nucleotides for their function and survival. Mutations can disrupt this pathway, leading to photoreceptor degeneration and vision loss.

Protein structure: The IMPDH1 gene encodes a protein of 514 amino acids that functions as a homotetramer. The protein structure consists of two main domains: a larger catalytic domain and a smaller regulatory domain. The catalytic domain is a TIM barrel structure that binds the substrate (IMP) and the cofactor (NAD+), facilitating the enzymatic conversion of IMP to XMP. The regulatory domain, also known as the Bateman domain, protrudes from the catalytic core and is composed of two tandem cystathionine beta-synthase (CBS) motifs. This domain is responsible for binding allosteric regulators, such as ATP and guanine nucleotides, which modulate the enzyme's activity. In the retina, alternative splicing produces unique IMPDH1 isoforms that contain additional amino acid extensions at the N-terminus and/or C-terminus. These retinal-specific variants maintain the core tetrameric structure but exhibit distinct regulatory properties. A notable structural feature of IMPDH1 is its ability to assemble into large, dynamic filamentous structures (polymers) under certain physiological conditions, such as high metabolic demand or specific light exposures. These filaments are formed by the stacking of IMPDH octamers and are thought to protect the enzyme from feedback inhibition, allowing for sustained GTP production in photoreceptor cells.

Molecular function: The IMPDH1 gene encodes the enzyme inosine-5'-monophosphate dehydrogenase 1, which catalyzes the rate-limiting step in the de novo synthesis of guanine nucleotides. Specifically, it oxidizes inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), with the concurrent reduction of NAD+ to NADH. This biochemical activity is crucial for maintaining the cellular pool of guanine nucleotides (GTP and dGTP), which are essential for DNA and RNA synthesis, signal transduction, and energy transfer. In the retina, IMPDH1 plays a specialized and critical role due to the exceptionally high demand for GTP. Photoreceptor cells require large amounts of GTP to produce cyclic GMP (cGMP), a key signaling molecule in the visual phototransduction cascade. In the dark, cGMP keeps cation channels open, maintaining the photoreceptor's resting membrane potential. Upon light exposure, cGMP is rapidly hydrolyzed, leading to channel closure and hyperpolarization of the cell. IMPDH1 ensures a continuous supply of GTP to replenish cGMP levels. Furthermore, IMPDH1 activity and localization in photoreceptors are dynamically regulated by light. The enzyme can form filamentous ultrastructures in response to high demand for guanine nucleotides or changes in illumination. These filaments are thought to play a role in allosteric regulation, maintaining a protein conformation that resists GTP-mediated inhibition, thereby ensuring sustained GTP production during prolonged light exposure. The ability of IMPDH1 to bind single-stranded nucleic acids also suggests potential roles in RNA/DNA metabolism or translational regulation within the retina.

Expression pattern: The IMPDH1 gene is ubiquitously expressed across a wide range of human tissues, but it exhibits particularly robust expression in the retina. Within the retina, IMPDH1 is the predominant isoform and is highly expressed in both rod and cone photoreceptor cells. The expression is notably strong in the photoreceptor inner segments, where the energy demand and requirement for guanine nucleotides are exceptionally high. In addition to the canonical transcript, the retina expresses unique splice variants of IMPDH1 that have extensions at both the N- and C-termini. These retinal-specific isoforms are thought to play specialized roles in the visual cycle and photoreceptor maintenance. The expression and activity of IMPDH1 in the retina are also regulated by light exposure, with changes in illumination leading to alterations in enzyme phosphorylation and the formation of dynamic protein filaments within the photoreceptors.

Mutation spectrum: The mutation spectrum of the IMPDH1 gene primarily consists of missense mutations, which account for the vast majority of pathogenic variants associated with inherited retinal diseases. Other types of mutations, such as in-frame deletions, nonsense mutations, frameshifts, and intronic variants, have also been reported but are less common. These mutations are typically inherited in an autosomal dominant manner, causing RP10, though rare de novo mutations can cause Leber congenital amaurosis (LCA). Mutations are distributed across the gene, but certain regions appear to be hotspots. For instance, Exon 10 has been identified as a significant hotspot, harboring numerous pathogenic variants. The mutations often affect critical functional domains of the protein, such as the CBS domains (Bateman domain) involved in allosteric regulation, or the catalytic TIM barrel domain. To date, over 50 distinct pathogenic or likely pathogenic variants have been identified in the IMPDH1 gene, contributing to approximately 2% to 5% of all autosomal dominant retinitis pigmentosa cases.

Pathogenic variants: 1. p.Asp226Asn (c.676G>A) - This is one of the most common and well-characterized mutations, frequently associated with autosomal dominant retinitis pigmentosa (RP10). It affects the catalytic domain and is known to cause significant loss of both rod and cone function. 2. p.Arg224Pro (c.671G>C) - Another frequent missense mutation linked to adRP. Like p.Asp226Asn, it was one of the first mutations identified in IMPDH1 and has been extensively studied for its effects on nucleic acid binding and protein aggregation. 3. p.Thr116Met (c.347C>T) - A missense mutation identified in families with adRP, affecting the regulatory Bateman domain of the protein. 4. p.Val268Ile (c.802G>A) - A pathogenic variant associated with adRP, located within the catalytic core of the enzyme. 5. p.Lys314Gln (c.940A>C) - A recently reported likely pathogenic variant found in a family with early macular involvement and diffuse outer retinal atrophy.

Clinical significance: Mutations in the IMPDH1 gene are primarily associated with autosomal dominant retinitis pigmentosa 10 (RP10) and, less commonly, Leber congenital amaurosis (LCA). IMPDH1-associated retinopathy typically presents early in life, most frequently in the first decade, with early macular involvement. Patients often experience night blindness as an initial symptom, followed by progressive peripheral vision loss and retinal degeneration with pigmentary changes. The disease is characterized by early-onset and severe visual loss, with initial rod alterations followed by cone involvement. The severity and progression of the disease can vary, but it generally leads to significant visual impairment. In some cases, the condition can present as a more severe and early-onset form, such as LCA, which is characterized by severe visual impairment or blindness from birth or within the first few months of life. The clinical manifestations are primarily restricted to the eye, with no significant systemic features typically associated with IMPDH1 mutations. Diagnostic imaging, such as fundus autofluorescence (FAF) and optical coherence tomography (OCT), often reveals diffuse outer retinal atrophy, early macular involvement with macular hyperautofluorescence surrounded by hypoautofluorescence, and progressive loss of the foveal ellipsoid zone. Full-field electroretinogram (ffERG) typically shows reduced or absent rod and cone responses, consistent with a rod-cone dystrophy.

Inheritance: Autosomal Dominant

Chromosomal location: 7q32.1

Genotype-phenotype correlations: Genotype-phenotype correlations in IMPDH1-associated retinopathy are complex and not fully understood. However, certain patterns have emerged from clinical studies. Most pathogenic variants in IMPDH1 cause autosomal dominant retinitis pigmentosa (RP10), which typically presents with early-onset night blindness and progressive visual field loss. The most common mutation, p.Asp226Asn, is associated with a classic RP phenotype, causing significant loss of both rod and cone function. Some specific mutations, such as de novo variants, have been linked to the more severe Leber congenital amaurosis (LCA) phenotype, which presents with profound visual impairment from birth. The location of the mutation within the protein domains may also influence the phenotype. Variants located in the Bateman (regulatory) domain versus the catalytic domain might have different effects on enzyme regulation, filament formation, or protein aggregation, potentially leading to variations in disease severity, age of onset, or progression rate. However, significant intrafamilial and interfamilial variability exists, suggesting that other genetic or environmental factors may also modify the disease expression.

Research and therapeutic approaches: Currently, there are no FDA-approved targeted therapies specifically for IMPDH1-associated inherited retinal diseases. Management primarily focuses on supportive care, including the use of low-vision aids, orientation and mobility training, and regular ophthalmologic monitoring to manage complications such as cataracts or macular edema. Vitamin A supplementation, which has been historically used for some forms of retinitis pigmentosa, should be discussed with a specialist, as its efficacy and safety can vary depending on the specific genetic cause. Research into potential therapeutic approaches is ongoing, with gene therapy being a major area of interest. Since IMPDH1 mutations typically cause disease through a dominant-negative effect or gain-of-function (such as abnormal protein aggregation), traditional gene replacement therapy (like Luxturna for RPE65) may not be sufficient. Instead, strategies such as "knockdown and replace" are being explored. This involves using RNA interference (RNAi) or antisense oligonucleotides (ASOs) to suppress the expression of the mutant IMPDH1 allele, combined with the delivery of a functional, engineered IMPDH1 gene that is resistant to the knockdown agent. Other investigational approaches include the use of small molecules to modulate IMPDH1 enzyme activity, prevent abnormal filament formation, or correct protein misfolding. Animal models, particularly zebrafish and mice, are actively being used to test these therapeutic strategies. While these approaches are still in the preclinical or early clinical stages, they hold promise for developing effective treatments for IMPDH1-associated retinopathy in the future.

Diagnostic testing: Diagnostic testing for IMPDH1-associated inherited retinal diseases typically involves molecular genetic testing. Panel-based genetic testing for inherited eye diseases is highly accurate and reproducible, and it is often the preferred initial approach. These panels typically include IMPDH1 along with other genes known to cause retinitis pigmentosa and Leber congenital amaurosis. If panel testing is inconclusive, more comprehensive approaches like whole exome sequencing (WES) or whole genome sequencing (WGS) may be employed to identify pathogenic variants. Genetic counseling is a crucial component of the diagnostic process. Since IMPDH1 mutations are primarily inherited in an autosomal dominant manner, each child of an affected individual has a 50% chance of inheriting the mutated gene. Genetic counselors can help families understand the inheritance pattern, the implications of the diagnosis, and the potential risks to other family members. They can also discuss the availability of prenatal testing or preimplantation genetic diagnosis for at-risk pregnancies.

Animal models: Animal models have been instrumental in understanding IMPDH1-associated retinal degeneration. The zebrafish model has proven particularly valuable, as zebrafish possess a highly conserved IMPDH1 retinal isoform that produces the majority of guanine in photoreceptors and forms dynamic protein filaments in both rod and cone cells. Studies in zebrafish have shown that these filaments change length and cellular distribution throughout the day, and loss of Impdh1a results in a substantial reduction of guanine levels, highlighting its critical role in purine nucleotide homeostasis. Mouse models have also been utilized to study the endogenous function of IMPDH1 and the effects of pathogenic mutations. Research in mice indicates that IMPDH1 plays a role in cGMP synthesis during prolonged bright light exposure, correlating with enzyme phosphorylation and filament formation. These models help researchers investigate how mutations might disrupt normal cGMP metabolism or cause protein misfolding and aggregation, leading to photoreceptor degeneration.

Population genetics: Mutations in the IMPDH1 gene are a relatively rare cause of inherited retinal diseases, accounting for approximately 2% to 5% of all cases of autosomal dominant retinitis pigmentosa (adRP) worldwide. The carrier frequency in the general population is very low, consistent with the rare, dominant nature of the disease. While IMPDH1 mutations have been identified in various ethnic groups, certain variants may be more prevalent in specific populations due to founder effects. For example, the p.Asp226Asn mutation is one of the most frequently observed variants in North American and European cohorts. However, large-scale population genetics data specific to IMPDH1 carrier rates remain limited, and the prevalence can vary significantly depending on the geographic region and the specific population studied.

Selected references: 1. Bowne SJ, et al. Spectrum and Frequency of Mutations in IMPDH1 Associated with Autosomal Dominant Retinitis Pigmentosa and Leber Congenital Amaurosis. Invest Ophthalmol Vis Sci, 2006. PMID: 16384941 2. Sakti DH, et al. IMPDH1-associated autosomal dominant retinitis pigmentosa. Ophthalmic Genet, 2023. PMID: 37226845 3. Cleghorn WM, et al. A highly conserved zebrafish IMPDH retinal isoform produces the majority of guanine and forms dynamic protein filaments in photoreceptor cells. J Biol Chem, 2021. PMID: 34813793 4. Burrell AL, et al. IMPDH1 retinal variants form filaments that resist GTP inhibition. Elife, 2022. PMID: 35103591 5. Bowne SJ, et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet, 2002. PMID: 11875050 6. Aherne A, et al. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Hum Mol Genet, 2004. PMID: 14722158